Discern Health Co-Authors JITC Article on Quality Measures for Cancer Immunotherapy

February 2020

In conjunction with the Society for Immunotherapy of Cancer (SITC), Discern Health Partner Tom Valuck and Director David Blaisdell co-authored the new Journal of ImmunoTherapy of Cancer (JITC) article, “Defining Current Gaps in Quality Measures for Cancer Immunotherapy: Consensus Report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit.”

The article identifies four National Quality Strategy domains with significant gaps. These findings are based on a SITC-convened, multi-stakeholder expert panel facilitated by Discern, which was created to identify current gaps in measures of quality cancer care delivery related to immunotherapy and to advance priority concepts surrounding quality measures that could be developed and broadly adopted by the field. This work is a first step toward defining and standardizing quality delivery of cancer immunotherapy.

Read the article here.

For more information, please contact Gracelena Ignacio at gignacio@discernhealth.com.

New Report: Recommendations for Patient and Family Engagement in Measure Development

Harnessing the stories, ideas, and innovations of patient and caregiver partners is the key to making measurement meaningful. With support from the Patient-Centered Outcomes Research Institute (PCORI)...
Learn More

About

About

Capabilities

Capabilities

Contact

Contact Us

Insights

Insights

Guy D’Andrea Speaks About Innovative Payment Models

Click here to view the VIDEO